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Abstract
Background: DYT-5 dystonia usually presents as a dopa-responsive dystonia (DRD) with early or late parkinsonian manifestations and/or dystonic features.
Genetically, these patients have been described as having a wide array of independent mutations in the guanosine triphosphate cyclohydrolase 1 gene (GCH1), and
these patients may also have a wide array of clinical manifestations.
Methods: A Colombian family with six affected female members was characterized.
Results: Three members, including the index case, revealed mild parkinsonism, whereas three granddaughters of the index case showed severe generalized
dystonia. No men were affected. There was anticipation, and a female predominance was uncovered. Treatment with levodopa was generally effective except in a
case with severe skeletal deformities and contractions. Detailed genetic analysis in the index case revealed a new mutation in exon 1 of GCH1 (c.159delG).
Discussion: This study revealed a new mutation of GCH1 that resulted in heterogeneous clinical presentations of DRD within a large family.
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Introduction
DYT-5 dystonia is an autosomal dominant hereditary dopa-responsive
dystonia (DRD), first described by Segawa et al. in 1976.1 Since the
original description, many mutations and clinical presentations have been
described.2-5 Characteristic features of DYT-5 dystonia include general-
ized dystonia and parkinsonism often with diurnal fluctuations. These
symptoms usually respond to low dose levodopa without dyskinesia or
wearing-off episodes commonly observed in common Parkinson’s disease
(PD).2-4,6 DYT-5 dystonia is associated with mutations in the guanosine
triphosphate cyclohydrolase 1 gene (GCH1) on chromosome 14 q21.1-
q22.2.4,7 More than 200 mutations have been reported in the gene (see
The Human Gene Mutation Database [HGMD]: http://www.hgmd.cf.
ac.uk/ac/gene.php?gene5GCH1 for a complete published list of
mutations). DYT-5 dystonia exhibits reduced penetrance and highly
variable expressivity. Women are more commonly affected than men. The
prevalence of DYT-5 dystonia is approximately one or two in every two
million individuals.3
The usual clinical presentation includes lower limb dystonia with
progressive walking difficulties, and rapid involvement of all four
extremities, the trunk, and the head. There are three described clinical
phenotypes: early onset (below age 20) with episodic dystonia, toe
walking, or progressive scoliosis; infantile onset with hypotonia followed
by early onset severe dystonia;8 adult-onset (above age 30) with non-
tremor parkinsonian type features and mild dystonia or possibly focal
dystonia type.6 Tremor, writer’s cramp, and cerebellar signs with
saccadic eye alterations can also occur in DYT-5 dystonia cases.9 Due to
the variety of clinical presentations, the disease can be misdiagnosed, and
cerebral palsy or parkinsonism are the most common misdiagnoses.10,11
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We report a novel DYT-5 mutation in the GCH1 gene with a
variable phenotype that occurred within a single Colombian family.
Methods
We describe a Colombian family with a DRD phenotype. The
pedigree for the family is summarized in Figure 1. The index case was an
82-year-old, right-handed female (number 1 in the pedigree). She
married three times. She had a daughter with similar clinical
manifestations (number 2 in the pedigree). Her daughter had an affected
daughter with dystonic features (number 3 in the pedigree). The index
case had two affected granddaughters with her first husband (numbers 4
and 5). With her third husband, she also had a granddaughter with
dystonic features (number 6). All of the unaffected family members
underwent neurological examination, and no abnormalities were
discovered. The clinical evaluations were performed by the same
movement disorders fellowship-trained neurologist (O.B-P.) in Colombia.
Results
Case 1 (Index case)
The index case was an 82-year-old, right-handed female. She
gradually developed tremor, rigidity, bradykinesia, and gait abnormality
at age 41. These issues developed after her last child was delivered. She
also had shuffling, slow and small steps, and some postural instability.
She had been medicated for 20 years with levodopa/carbidopa 250/
25 mg, one tablet daily. She reported a good response to therapy without
any side effects. During the examination, she was able to perform her
activities of daily living without difficulties. Magnetic resonance imaging
(MRI) was normal. Blood chemistry, including serum copper, was
normal. Neuropsychological evaluations were normal.
Cases 2 and 3
Case 2 was a 53-year-old female who was the daughter of the index
case. Her symptoms began when she was approximately 40 years old.
Case 3 was a 36-year-old female who was the daughter of Case 2, and
her symptoms began at age 31. The response to levodopa in both cases
was adequate and similar to that of the index case. Both were treated
with levodopa/carbidopa 250/25 mg one tablet every morning, and
motor function and activities of daily living were essentially normal
when in the ‘‘on’’ state. There were no reported side effects.
Case 4
Case 4 was a 28-year-old female, the granddaughter of the index
case, who developed symptoms around age 7, including abnormal
postures of her feet and twisting movements that produced unsteadi-
ness. She was initially diagnosed with cerebral palsy. The severity of
the disease required devices for gait assistance. In a very short period of
time (months to years), she developed abnormal postures of her legs
and arms with twisted postures of her head and trunk. She required
assistance in activities of daily living, however she did not develop
cognitive issues. MRI and blood chemistry were normal. Due to the
original diagnosis and the persistence of her symptoms, she underwent
a bilateral tenosynovectomy and later a surgical hip dislocation at age
9. Despite three surgeries and multiple physical therapy sessions, her
symptoms did not improve. She was bedridden with generalized
contractures. At age 26, she received a treatment with levodopa/
carbidopa 250/25 mg half tablet daily, which produced nausea. She
later received biperiden, which partially relieved her contractures.
Case 5
The 18-year-old sister of case 4 developed abnormal postures of the
feet and twisting movements around age 7. She also required assistant
for gait. MRI, blood chemistry, and neuropsychological evaluation
were all normal. At age 16, she received levodopa/carbidopa 125 mg
in the morning with an excellent response, and her activities of daily
living were normal after 3 months of treatment. She had returned to
school.
Case 6
Case 6 was a 13-year-old female of the third son of the index case.
At the age of 6, she developed contractures in both legs, and after a
short period of time the symptoms progressed to involve her arms and
also produced abnormal painful postures that persisted both during the
day and night. She required assistance in her activities of daily living,
and she became dependent on a wheelchair. At age 11, she received a
trial of levodopa/carbidopa 250/25 mg half tablet every morning with
a good response, and she became independent in her activities of daily
living and ambulation. She became able to go to school.
Genetic analysis
Only the index case was tested. Each of the protein-coding exons of
GCH1 was polymerase chain reaction-amplified and sequenced using
standard protocols. Conditions and primer sequences are available
upon request. Sequence data, produced on an ABI3730 genetic
analyzer (Applied Biosystems, Foster City, CA), was visualized using
Sequencher (Gene Codes Corp, Ann Arbor, MI). Review of the
chromatograms from this sequencing revealed a deletion in exon 1 of
GCH1 (c.159delG, based on sequence accession number NM_000161),
which resulted in a frame shift and the creation of a premature stop
codon p.W53X (based on sequences accession number NP_000152.1).
See attached chromatogram, which displays the sequences (Figure 2).
Figure 1. Pedigree of a Colombian Family with DYT-5 dystonia. Only
women affected. Genetic analysis in the index case (arrow) revealed a new
mutation in exon 1.
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Discussion
We discovered an index case in a Colombian family with a clinical
course revealing a mild parkinsonism that could have been mistaken for
idiopathic PD. Also, severe dystonia emerged in multiple offspring and
in multiple generations. A wide array of clinical and genetic variability in
DYT-5 dystonia has been previously reported.12 Generalized or focal
dystonic features and parkinsonian and cerebellar manifestations have
been observed. The various presentations can make diagnosis difficult.
Variation in expressivity, even within members of the same family, has
also been reported,13 and although genetic testing is now available, most
experts would reason that a levodopa-challenge test should be attempted
whenever the diagnosis is suspected. In our cases, all patients exhibited a
good response to levodopa, except the most affected woman who had
severe bony contractions.
Interestingly, this family’s genetics analysis revealed evidence for
female-dominant penetration with anticipation (worsening in succes-
sive generations). Gender preference for females has been reported in
DRD.14 Although a mechanism for such an effect in a disease caused
by a stable point mutation remains unclear, the reduced penetrance
associated with GCH1 mutations would suggest that there are other
genetic, environmental, or stochastic factors mediating the disease
process, and that these factors may be responsible for the apparent
anticipation and severe clinical manifestations in the index case’s three
granddaughters.
In conclusion, a new stop mutation in exon 1 of GCH1 (c.159delG)
was found in a Colombian family. The clinical features of this family
included female dominance and anticipation.
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